13 August 2014
EMA/427398/2014
Procedure Management and Business Support Division

Paediatric Committee (PDCO)

Minutes of the 16-18 July 2014 meeting

Chair: Dirk Mentzer - Vice-chair: Koenraad Norga

Note on access to documents

Some documents mentioned in the agenda/minutes cannot be released at present following a request for access to documents under Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).

Disclaimers

Some of the information contained in the PDCO discussions is considered commercially confidential or sensitive and therefore not disclosed in the present minutes. With regards to therapeutic indications listed against products it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. The procedures discussed by the PDCO are on-going and therefore certain aspects of them are considered confidential. Additional details on these procedures will be disclosed in the PDCO Committee meeting reports (after the PDCO Opinion is adopted), and on the Opinions and decisions on paediatric investigation plans webpage (after the EMA Decision is issued). Documents mentioned in these minutes cannot be released at present as they are currently in draft format or are classified as confidential. They will become public when adopted in their final form or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006). Of note, this set of minutes is a working document primarily designed for PDCO members and the work the Committee undertakes.

I Introduction

I.1 Adoption of the minutes from previous meeting

The Minutes of the PDCO plenary session held 22-23 May 2014 were adopted.

http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/document_listing/document_listing_000192.jsp&mid=WC0b01ac0580028eab

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555
Send a question via our website www.ema.europa.eu/contact

I.2 Adoption of the Agenda

The agenda was adopted with amendments.
http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/document_listing/document_listing_000192.jsp&mid=WC0b01ac0580028eab

All decisions taken at this meeting were made in presence of a quorum of members – i.e. 23 or more members were present in the room.

I.3 Declaration of Conflict of Interest

See Annex I

I.4 External attendance

Please refer to the July 2014 PDCO monthly report published on the EMA Website:

http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/document_listing/document_listing_000192.jsp&mid=WC0b01ac0580028eab

I.5 Leaving/New Members and Alternates

Please refer to the July 2014 PDCO monthly report published on the EMA Website:

http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/document_listing/document_listing_000192.jsp&mid=WC0b01ac0580028eab

II Opinions

II.1 Opinions on Products

II.2 Opinions on Compliance Check

II.3 Opinions on Modification of an Agreed Paediatric Investigation Plan

Please refer to the July 2014 PDCO monthly report published on the EMA Website:

http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/document_listing/document_listing_000192.jsp&mid=WC0b01ac0580028eab

III Discussion of applications

The PDCO discussed total n. 83 procedures in total[1], of which:

- 30 paediatric investigation plan applications;
- 7 product-specific waiver applications;
- 8 compliance check procedures (interim and final);
- 38 requests for modifications of an agreed paediatric investigation plan.

[1] The procedures discussed by the PDCO are on-going and therefore are considered confidential. Additional details on these procedures will be disclosed in the PDCO Committee meeting reports (after the PDCO Opinion is adopted), and on the Opinions and decisions on paediatric investigation plans webpage (after the EMA Decision is issued).

IV Nomination

IV.1 Nomination of Rapporteurs and Peer reviewers

• List of letters of intent received for submission of applications with start of procedure September 2014[1] for Nomination of Rapporteur and Peer reviewer • Nomination of Rapporteur for requests of confirmation on the applicability of the EMA decision on class waiver	Adopted

IV.2 Nomination for other activities

• No requests for nominations were received	

V Update and finalisation of opinions and requests for modification

The opinions adopted during the Paediatric Committee meeting of July 2014 are published in the same month's meeting report published in the EMA website: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/document_listing/document_listing_000192.jsp&mid=WC0b01ac0580028eab.

VI Discussion on the applicability of class waiver

Active substance	Proposed indication	Condition	Outcome	Potential paediatric interest of this medicine suggested by PDCO
Fluticasone furoate/umeclidinium bromide	Treatment of patients with COPD, including those with an asthmatic component	Treatment of Chronic Obstructive Pulmonary Disease (COPD) (excluding chronic lung diseases associated with long-term airflow limitation, such as asthma, bronchopulmonary dysplasia, primary cilia dyskinesia, obstructive lung disease related to graft-versus-host disease after (bone-marrow transplantation)	Confirmed	Treatment of asthma or other chronic obstructive lung diseases in children

Active substance	Proposed indication	Condition	Outcome	Potential paediatric interest of this medicine suggested by PDCO
Rilapladib (SB-659032)	Adjunctive treatment of patients with mild Alzheimer's dementia with neuroimaging evidence of cerebral small vessel disease to slow cognitive and functional decline	Treatment of Alzheimer's disease	Confirmed	Not applicable
Tiprelestat	Prevention of postoperative complications after resection of oesophageal cancer	Treatment of adenocarcinoma of the colon and rectum Treatment of gastric adenocarcinoma Treatment of oropharyngeal, laryngeal or nasal epithelial carcinoma Treatment of gastric carcinoids	Not confirmed, because the mechanism of action of the medicinal product targets the healing process of any lesion (iatrogenic and non-iatrogenic) and is therefore unrelated to the proposed class waiver conditions. In addition, the proposed prophylactic indication for oesophageal cancer is not covered by the therapeutic conditions of the class waiver Agency Decision which target other organs.	Burns, coronary artery bypass surgery, pulmonary arterial hypertension, kidney transplantation, prevention of post-operative complications in any surgical procedures, promotion of patency of any fistulas

VII Discussion on the inclusion of an indication within a condition in an agreed PIP/waiver

No requests were received for the month of July.

VIII Annual reports on deferrals

Annual report based on PIP decision for	Substances (abbrev.)	Product Name	Orphan	Difficulties progressing the PIP?	Outcome
EMEA-000117-PIP01-07	ipilimumab	Strentarga	No	Yes	The PDCO noted the report; a modification of the agreed PIP is planned.
EMEA-000117-PIP02-10	ipilimumab	Yervoy (subject to change during MAA procedure)	No	No	The PDCO noted the report.
EMEA-000548-PIP01-09	Beclometasone dipropionate plus formoterol fumarate dihydrate	Foster and Kantos and associated names, Kantos Master and Inuvair and associated names	No	No	The PDCO noted the report.
EMEA-000979-PIP01-10	autologous cartilage derived cultured chondrocytes	MACI Implant	No	No	The PDCO noted the report.
EMEA-000727-PIP01-09	Bosutinib (SKI-606)	Bosulif	Planned	Yes	The applicant considers the PIP not applicable anymore and the applicant is planning to apply for a modification by the second quarter of 2015. The PDCO

Annual report based on PIP decision for	Substances (abbrev.)	Product Name	Orphan	Difficulties progressing the PIP?	Outcome
					commented that the modification should be requested earlier than planned.
EMEA-000916-PIP01-10	Lixisenatide	Lyxumia	No	Yes	Recruitment difficulties were reported. A request for modification of the agreed PIP is planned in September 2014.
EMEA-000408-PIP01-08	Icatibant acetate	Firazyr	Yes	No	The PDCO noted the report.
EMEA-000876-PIP01-10	Eculizumab	Soliris	Yes	Yes	The applicant has submitted a request for modification to postpone the completion date of the remaining ongoing study.
EMEA-000876-PIP02-11-M01	Eculizumab	Soliris	Yes	No	The PDCO noted the report.
EMEA-000128-PIP01-07	Liraglutide	Victoza	No	Yes	Recruitment difficulties and issues with ethics committees were reported. A request for modification of the agreed

Annual report based on PIP decision for	Substances (abbrev.)	Product Name	Orphan	Difficulties progressing the PIP?	Outcome
					PIP is planned later this year.
EMEA-000128-PIP02-09	Liraglutide	Victoza	No	No	The PDCO noted the report.
EMEA-000157-PIP01-07-M01	Belatacept	Nulojix	No	No	The PDCO noted the report.
EMEA-000335-PIP01-08	N-(2,4-Di-tert-butyl-5-hydroxyphenyl)-1,4-dihydro-4-oxoquinoline-3-carboxamide	Kalydeco	Yes	No	The PDCO noted the report.
EMEA-000520-PIP01-08	belimumab	Benlysta	No	Yes	The PDCO noted the report.
EMEA-001186-PIP01-11	ponatinib	Iclusig	Yes	Yes	The PDCO noted the report.
EMEA-000467-PIP01-08	Perampanel	Not available	No	Yes	The PDCO noted the report; a modification of the agreed PIP is planned.

IX Other topics

Guidelines	
Guideline on asthma Marek Migdal	A summary of the comments related to the paediatric chapter of the guideline was presented to the PDCO. Committee members were requested to submit their comments to EMA to allow the Committee to adopt a revised paediatric chapter at next plenary meeting.
Working groups	
Paediatric consultation meeting – update and way forward	Breakout session took place in the margins of the PDCO plenary meeting.

Paediatric inventory	The therapeutic areas oncology and ophthalmology were discussed.
Paediatric oncology	Breakout session took place in the margins of the PDCO plenary meeting.
Formulation	No non-product related issues were reported to the Committee.
Non-Clinical	No non-product related issues were reported to the Committee
Other topics	
CHMP update on paediatric topics	The PDCO members were informed about the CHMP opinions on 3 medicinal products with paediatric indication and corresponding PIPs adopted in June 2014.
Optimisation of PDCO plenary Dirk Mentzer	The Committee was informed on the start of an initiative to improve operational conduct of PDCO meetings. PDCO members express their interest to join the Chair in this improvement exercise.
Training of new PDCO members	The draft training programme for new PDCO members was presented.
EMA road map, EMA work programme and development of PDCO work plan	The secretariat presented the process that will guide the drafting of a PDCO work plan. PDCO members express their interest to join the Chair in an initial brainstorming to identify activity areas, objectives and activities.
Art.31 referral of Hydroxyzine, PRAC List of Questions to be addressed by the PDCO Sylvie Benchetrit	The background information linked to this Art.31 referral of Hydroxyzine to PRAC and the list of questions to be addressed by the PDCO were presented and discussed during the plenary meeting. PDCO members were asked to provide written responses to the specific questions before the next plenary meeting so that these could be presented and endorsed by PDCO members in August 2014. The adopted PDCO responses will then be sent to PRAC by end of August 2014.
Update on Enpr-EMA activities	The PDCO Chair, who also is the PDCO representative within the Enpr-EMA coordinating group, summarised the one and a half day long meeting, consisting of three parts: the annual workshop open to all

	stakeholders, including industry and patient group representatives; the network member meeting and the coordinating group meeting. The most promising and positive impression shared by all workshop participants was the work done by the several working groups established a year ago. The presentations of the open workshop are published on the Enpr-EMA website; the reports off all three meetings will be published soon at the Enpr-EMA website.
Serious adverse events in and safety concerns for children with acute lymphoblastic leukaemia being treated with clofarabine in combination with anti-cancer medicines Sylvie Benchetrit	The PDCO exchanged experience on the topic and is preparing an Opinion in response to questions raised by a national competent authority.
Paediatric formulary Anthony Nunn, Siri Wang	The PDCO was informed about the Pan-European Paediatric Formulary and what the project aims to achieve.
DTaP Vaccine PIP (VWP feedback)	The Paediatric Committee endorsed the changes proposed by the VWP and proposed a revision of a paragraph on background immunisation which seemed unclear according to the comments received. The updated version is submitted to the CHMP for adoption.
Compliance report for Cobicistat / atazanavir sulphate EMEA-C1-001465-PIP01-13 Adopted on 2 July 2014	The PDCO members were informed about finalisation of this partial compliance check on 2 July 2014 through a written procedure.
Compliance report for asfotase alfa EMEA-C2-000987-PIP01-10-M02 Adopted on 11 July 2014	The PDCO members were informed about finalisation of this partial compliance check through a written procedure.
Visit to 30 Churchill Place	A visit of the new EMA premises took place on Wednesday 16 July 2014

Paediatric consultation meeting – update and way forward	An early dialogue will help from a public health perspective to raise awareness on the paediatric development and support companies to face ethical and technical challenges in conducting and planning paediatric studies. The aim will be to facilitate the integration of the paediatric development in their global strategy by identifying the timing and involvement of key players alongside the paediatric development life cycle from the early phase of a development to the SmPC. PDCO position on how to handle the paediatric development life cycle will be ready at the end of September PDCO for discussion with SAWP and CHMP representatives.
PDCO response to the questions from PRAC on the Chlorhexidine (CHX) procedure Angeliki Siapkara, Dina Apele-Freimane	The PDCO discussed safety issues of the use of CHX specifically in preterm neonates and the situation that apparently a variety of regional/hospital recommendations and products exist in different Members States. However, it was also highlighted that there is an unmet therapeutic need for safe and efficacious products, licensed for neonates including preterm infants. The response to the PRAC was adopted.
D30 Products identified for the Non-Clinical Working Group Jacqueline Carleer	Documents tabled for information

Any other business

- EFGCP-DIA-EMA Paediatric Conference (30 Sep-01 Oct 2014): The PDCO received the draft agenda for their information

Annex I to the Minutes of the PDCO of July 2014

Documentation on Declaration of interest of members, alternates and experts

Based on the Declarations of interest submitted by the Committee members, alternates and experts and based on the topics in the agenda of the current meeting, the Committee Secretariat announced the restricted involvement of Committee members for the upcoming discussions.

In accordance with the Agency's revised Policy and Procedure on the handling of conflicts of interests, participants in this meeting were asked to declare any conflict of interests on the matters for discussion (in particular any changes, omissions or errors to the already declared interests).

No new or additional conflicts were declared.

Member, alternate, expert name	Outcome restriction following evaluation of electronic evaluation form	Topics on the current Committee Agenda for which this restriction applies
Adriana Ceci	Restriction level DP	EMEA-000788-PIP02-11-M03
Adriana Ceci	Restriction level DP	EMEA-000081-PIP01-07-M07
Adriana Ceci	Restriction level DP	EMEA-001043-PIP01-10-M01
Adriana Ceci	Restriction level DP	EMEA-000380-PIP02-09-M02
Christoph Male	Restriction level XP/DP	EMEA-000788-PIP02-11-M03
Christoph Male	Restriction level XP/DP	EMEA-000081-PIP01-07-M07
Christoph Male	Restriction level DP	EMEA-C1-001114-PIP01-10-M02
Christoph Male	Restriction level DP	EMEA-C1-001064-PIP01-10-M02
Kevin Connolly	Restriction level XP	EMEA-000429-PIP01-08-M03
Marek Migdal	Restriction level DP	EMEA-001595-PIP01-13
Marek Migdal	Restriction level DP	EMEA-001599-PIP01-13
Marek Migdal	Restriction level DP	EMEA-000525-PIP01-08-M03
Violeta Iotova	Restriction level XP	EMEA-001533-PIP01-13
Violeta Iotova	Restriction level XP	EMEA-000479-PIP01-08-M02
Violeta Iotova	Restriction level XP	EMEA-000496-PIP01-08-M03

Discussions, deliberations and voting took place in full respect of the restricted involvement of Scientific Committee members and, where relevant, experts attending the plenary meeting, as announced by the Scientific Committee Secretariat at the start of meeting.

Restriction levels:

Evaluation of the conflict of interest	
Outcome	Impact
R-P	To be replaced for the discussions, final deliberations and voting as appropriate in relation to the relevant product or a competitor product.
XP	Where Individual product involvement is declared - PRODUCT INDICATION: - No involvement with respect to procedures involving the relevant product or a competitor product in the relevant indication i.e. no part in discussions, final deliberations and voting as appropriate as regards these medicinal products. - Cannot act as Rapporteur for these products - [Cannot act as Rapporteur for development of guidelines in concerned therapeutic area].
XC	Where cross product / general involvement is declared - COMPANY: - No involvement (as outlined above) with respect to products from the specified company. - Cannot act as Rapporteur for products from the relevant company(ies).
DP	Where Individual product involvement is declared - PRODUCT INDICATION: - Involvement in discussions only with respect to procedures involving the relevant product or a competitor product i.e. no part in final deliberations and voting as appropriate as regards these medicinal products. - Cannot act as Rapporteur for these products.
DC	Where cross product / general involvement is declared - COMPANY: - Involvement in discussions only with respect to products from the specified company. - Cannot act as Rapporteur on products from the relevant company(ies).
XR	Committee member cannot act as Rapporteur or Peer reviewer in relation to any medicinal product from the relevant company.
R-C	To be replaced for the discussions, final deliberations and voting as appropriate in relation to any medicinal product from the relevant company

Annex II to the Minutes of the PDCO of July 2014

List of Participants

Chair

Dirk MENTZER

Members appointed by Member States or CHMP

Karl Heinz HUEMER	Austria
Koenraad NORGA	Belgium
Violeta IOTOVA	Bulgaria
Marina DIMOV DI GUSTI	Croatia
Peter SZITANYI	Czech Republic
Marianne ORHOLM	Denmark
Pirjo LAITINEN-PARKONNEN	Finland
Sylvie BENCHETRIT	France
Birka LEHMANN	Germany
Grigorios MELAS	Greece
Agnes GYURASICS	Hungary
Kevin CONNOLLY	Ireland
Paolo ROSSI	Italy
Dina APELE-FREMIANE	Latvia
Romaldas MACIULAITIS	Lithuania
Carine de BEAUFORT	Luxembourg
Hendrik van den BERG	The Netherlands
Siri WANG	Norway
Marek MIGDAL	Poland
Helena FONSECA	Portugal (connected via Teleconference)
Dana Gabriela MARIN	Romania
Michaela MECIAKOVA	Slovak Republic
Stefan GROSEK	Slovenia
Fernando DE ANDRÉS TRELLES	Spain

Viveca Lena ODLIND	Sweden
Angeliki SIAPKARA	United Kingdom

Alternates appointed by Member States or CHMP

Christoph MALE	Austria
Jacqueline CARLEER	Belgium
Marta GRANSTRÖM	Denmark
Immanuel BARTH	Germany
Francesca ROCCHI	Italy
Herbert LENICKER	Malta (connected via Teleconference)
Jolanta WITKOWSKA-OZOGOWSKA	Poland
Hugo TAVARES	Portugal
Maria Jesus FERNANDEZ CORTIZO	Spain
Ninna GULLBERG	Sweden
Martina RIEGL	United Kingdom

Members representing patients' organisations

Tsveta SCHYNS-LIHARSKA	European Network for Research on Alternating Hemiplegia, Belgium

Members representing health care professionals

Adriana CECI	Member of the Italian Parliament and Vice-president of Committee on Health and Social Affairs, Italy
Anthony James NUNN	Alder Hey Children's Hospital, UK

Alternates representing health care professionals

Paolo PAOLUCCI	Polyclinic of Modena, Italy

Experts participating via Teleconference

Dr Vaskar SAHA	EMEA-001493-PIP01-13
Laurence BRUGIERES	EMEA-001493-PIP01-13
Jan TAMINIAU	EMEA-001511-PIP02-13

European Medicines Agency support

Meeting run with relevant support from the EMA staff